Alnylam Amends Agreements With Max Planck Society

Alnylam Pharmaceuticals a leading RNAi therapeutics company, has announced that it has signed an amendment to its agreements with Garching Innovation GmbH (Garching Innovation), the licensing agent for the Max Planck Gesellschaft (Max Planck Society). This amendment reinforces Alnylam's continued exclusivity for the so-called "Tuschl II" patent application, a critical fundamental patent for RNAi, and improves the operating flexibility for its wholly owned subsidiary, Alnylam Europe AG (Alnylam Europe).

()a href="http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050616005185&newsLang=en" target="_blank">Business Wire